Published in Cancer Weekly, January 18th, 2005
A.P. Venook and colleagues wrote, "Hepatocellular carcinoma (HCC) is an extremely diverse and heterogeneous disease and improving patient outcome is a difficult undertaking. While many therapeutic options exist, few have been subjected to rigorous study, so patient benefit is uncertain.
"Comparative trials need to be performed to determine the value of these and, of course, newer treatments. However, there are numerous challenges to the design and conduct of such studies."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.